Financials data is unavailable for this security.
View more
Year on year Cyclopharm Ltd has grown net income from a loss of -6.61m to a smaller loss of -4.70m primarily through revenue growth (24.96m to 27.77m). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales , the 11.22% growth in revenues contributed enough to still see net income improve.
| Gross margin | 64.77% |
|---|---|
| Net profit margin | -32.08% |
| Operating margin | -30.22% |
| Return on assets | -16.43% |
|---|---|
| Return on equity | -22.59% |
| Return on investment | -19.97% |
More ▼
Cash flow in AUDView more
In 2023, cash reserves at Cyclopharm Ltd fell by 8.57m. Cash Flow from Investing was negative at 508.47k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 7.20m for operations while cash used for financing totalled 1.02m.
| Cash flow per share | -0.0853 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.4278 |
|---|---|
| Tangible book value per share | 0.376 |
More ▼
Balance sheet in AUDView more
| Current ratio | 4.38 |
|---|---|
| Quick ratio | 3.42 |
| Total debt/total equity | 0.1172 |
|---|---|
| Total debt/total capital | 0.1049 |
More ▼
Growth rates in AUD
Year on year, growth in dividends per share fell -50.00% while earnings per share excluding extraordinary items rose 29.27%. Additionally, five year annualized dividend per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.53% |
|---|---|
| Div growth rate (5 year) | -12.94% |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -29.44 |
More ▼
